- Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream.
- Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema characterized by inflammation and intense itch.
- The company has submitted a Priority Review Voucher (PRV) along with the application for ruxolitinib cream. The use of the PRV shortens the review period by four months. The agency's action date is June 21.
- Price Action: INCY increased 0.55% at $82 on last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
